Merck has taken a step to make its antiviral pill available in poor nations, but many obstacles remain for broad access to coronavirus drugs.
Tag: Drugs (Pharmaceuticals)
Asia-Pacific Countries Rush to Buy Merck Covid Pill
The home treatment, molnupiravir, is said by the company to potentially halve the risk of hospitalization and death from the virus.
Pfizer Booster Can Be Given After 6 Months, European Drug Agency Says
The European Medicines Agency also said that extra doses of the Moderna and Pfizer-BioNTech vaccines could be given to people with underlying health conditions as early as 28 days after a second dose.
W.H.O. Backs Antibody Treatment For High-Risk Covid Patients
The expensive treatment, developed by the U.S. drug maker Regeneron and the Swiss biotech company Roche, has garnered attention as backstop for those who shun vaccines.
Pressure Grows on U.S. Companies to Share Covid Vaccine Technology
Moderna accepted $2.5 billion in taxpayer money to develop its Covid-19 vaccine. But officials in the U.S. and overseas are having trouble persuading the company to license its technology.
Study of Covid Booster Shot Benefits Fans Debate Over Extra Doses
Independent experts, including government scientists, were skeptical of the research from Israel, which included limited data over a short period.
Ivermectin Won’t Treat Covid-19, but Demand Is High Anyway
Clinical trials have repeatedly failed to show that the drug is effective against the virus. Still, U.S. demand is high.
Joe Rogan, A Podcasting Giant Who Has Been Dismissive of Vaccination, Has Covid
“I got fevers, sweats, and I knew what was going on,” he said in a video on Instagram on Wednesday, after returning from a series of shows in Florida.
An Experimental H.I.V. Vaccine Fails in Africa
Researchers ended a large trial in South Africa after finding that an experimental vaccine offered little protection.
Biden Falls Short on U.S. Vaccine ‘Arsenal’ Pledge, Experts Say
Congress appropriated $16 billion to ramp up Covid-19 countermeasures, but a new report found that the Biden administration had spent very little of it on expanding vaccine manufacturing capacity.